Appili Therapeutics Inc's stock has experienced notable movements this week amid recent financial disclosures.
Appili Therapeutics Inc (APLI.TO) saw its stock price rise by 50% on Monday, closing at C$0.01. This increase follows the company reporting its fiscal year 2026 financial and operational results, which have caught the attention of investors and analysts. Despite this week's gains, the stock remains down 40% year-to-date, reflecting ongoing challenges in the biotech sector.
Investor takeaway: Investors should consider the broader implications of Appili's recent announcements, particularly the termination of certain contracts and the potential for future funding. The stock's volatility, combined with a low trading volume compared to its average, suggests caution in evaluating its short-term movements.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.32M
52W high
$0.04
52W low
$0.01
1W change
+0.00%
Beta
-0.20
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
338.1%
Annualized
90-Day Vol
274.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 โ C$0.05 |
| 60 trading days | C$0.01 | C$0.00 โ C$0.07 |
| 90 trading days | C$0.01 | C$0.00 โ C$0.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Appili Therapeutics Inc's stock rose 50% today, but remains down 40% YTD.
Despite today's surge, the stock's performance over the past year has been challenging, with a 52-week trading range of C$0.01 to C$0.04, indicating limited upward momentum.
Bull case
The recent financial results indicate progress in Appili's commercial-stage programs and highlight non-dilutive funding initiatives. These developments could help stabilize the company's operations and funding base moving forward.
Bear case
The termination of the contract with NIAID and the end of the arrangement with Aditxt Inc. raises concerns about Appili's operational strategy and funding sources, which may impact investor confidence.
Price Action
Advertisement
Appili Therapeutics Inc's stock closed at C$0.01, reflecting a significant 50% increase on Monday. The stock has shown a 0% change over the past week, maintaining its position amidst fluctuating investor interest.
Company News
This week, Appili reported its fiscal year 2026 financial and operational results, emphasizing advancements in its commercial-stage programs and a focus on non-dilutive funding. However, the company also faced setbacks, including the termination of its contract for the VXV-01 program with NIAID, which could impact its future funding and operational strategy.
Technical Picture
Currently, Appili's stock is trading at the lower end of its 52-week range of C$0.01 to C$0.04. The stock's 50-day moving average stands at C$0.01, indicating a recent uptick of 13.6%. In contrast, the 200-day moving average is at C$0.02, showing a decline of 17.1% relative to the current price. With a beta of -0.20, the stock has demonstrated lower volatility compared to the market. The latest trading volume was 3,751 shares, significantly below the 20-day average volume of 85,975 shares, indicating a lack of investor engagement.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
